Lilly and Novo Nordisk both start selling obesity drugs straight to employers

Eli Lilly and Novo Nordisk are each rolling out ways for employers to get obesity drugs directly, cutting out some of the layers that typically sit between drugmakers and workplace health plans ^[1][2].

Lilly said its new model will launch in early 2026 and rests on three parts: flexible benefit designs so employers can shape obesity coverage for their own workforce, a dedicated pharmacy network meant to make costs easier to track, and partnerships with outside companies to build broader weight-management support ^[1]. Lilly executive vice president Ilya Yuffa called obesity care "the next frontier in employer health benefits," saying companies that act now will "close coverage gaps" and build healthier workforces ^[2].

Two partners are central to the rollout. Waltz Health, a health tech company focused on lowering drug costs, said it will make a direct-to-employer access model available starting January 1. Waltz describes the setup as combining fixed pricing for obesity drugs with real-time eligibility checks, prescription routing, and ongoing patient engagement ^[1]. Waltz CEO Mark Thierer said employers are "actively searching for solutions that make coverage both clinically responsible and financially viable" ^[1]. Separately, 9amHealth, a virtual cardiometabolic care provider, unveiled a "No Barriers Bundle" with Lilly that pairs drug access with its own care platform. 9amHealth co-founder Paul Geevarghese said rising costs and complexity have made obesity coverage "difficult to manage" for employers ^[1].

Reuters reports that Novo Nordisk is also involved in direct-to-employer programs with Waltz and 9amHealth, alongside Lilly ^[2]. A Novo Nordisk spokesperson told Reuters that "transparent initiatives like these enable more employers to opt in to coverage for authentic, FDA-approved GLP-1 medicines" ^[2]. Analysts cited by Reuters estimate the obesity drug market could reach $150 billion a year by the early 2030s, with Novo and Lilly currently dominating that market ^[2].

Lilly said the new employer model builds on a separate deal it and Novo Nordisk struck with the White House to lower prices for their weight-loss drugs, a move tied to Medicare, Medicaid, and cash-pay pricing announced earlier in November ^[1][2]. Reuters also notes both companies have been working to expand access to their brand-name drugs while pushing back against compounded, unapproved versions of the medications ^[2].

Why it matters for patients

For workers covered by an employer health plan, this shift could change how obesity drug coverage is decided and priced, since it moves some purchasing away from pharmacy benefit managers, the middlemen who negotiate rebates and often shape which drugs are covered and at what cost ^[1][2]. Whether this leads to lower costs, easier access, or different coverage rules for individual employees is not detailed in the sources, and the model has not yet launched. Patients whose employers adopt one of these programs may encounter new tools, like real-time eligibility checks or bundled care platforms, for enrolling in or managing their weight-management prescriptions ^[1]. It is not yet known how many employers will choose to participate, how pricing will compare to current PBM-negotiated rates, or how this affects patients who get coverage through other channels such as individual insurance or Medicare and Medicaid, where separate pricing changes were already announced ^[1][2].

What happens next

Lilly said it will work with its partners over the "next several months" to refine the program ahead of an early 2026 launch ^[1]. Waltz Health said its direct-to-employer access model will become available on January 1, 2026 ^[1]. Beyond those dates, the sources do not specify further milestones, such as which employers have signed on or how enrollment will work in practice.